| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5613835 | Journal of Arrhythmia | 2017 | 4 Pages |
Abstract
The ability of dabigatran to prevent thromboembolism is comparable to that of warfarin; however, the major bleeding rate is lower with dabigatran in “real-world” NVAF patients.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Miyoko PhD, Tsuyoshi MD, Takehiko MD, Atsushi MD, Kagari MD, Nobuhisa MD,